DATA SHEET - Medsafe
ATRIPLA Data Sheet v13.0 (16 November 2017) Page 3 of 36 should be used during the first days of ATRIPLA therapy in patients taking a CYP3A4 substrate
Download DATA SHEET - Medsafe
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
PL 00010/0643 - GOV.UK
www.mhra.gov.ukUKPAR Canesten HC Cream PL 00010/0643 8 NON-CLINICAL ASSESSMENT PHARMACODYNAMICS, PHARMACOKINETICS AND TOXICOLOGY As the pharmacodynamic, pharmacokinetic and toxicological properties of clotrimazole and
COMMITTEE FOR MEDICINAL PRODUCTS FOR …
www.ema.europa.euIt clarifies the requirements for clinical documentation for abridged applications for orally inhaled formulations and variations/extensions to a marketing authorisation, and including both single active substance products
Guideline on clinical development of fixed …
www.ema.europa.euThis is the nd2 revision of the guideline on clinical development of fixed combination medicinal products containing two or more active substances within a single pharmaceutical form.
INVESTIGATION OF BIOAVAILABILITY AND …
apps.who.int1 MALAYSIAN GUIDELINES FOR THE CONDUCT OF BIOAVAILABILITY AND BIOEQUIVALENCE STUDIES LOGO MINISTRY OF HEALTH, MALAYSIA Supported by Seminar on Clinical Trials and Bioequivalence Studies
GUIDELINES FOR BIOAVAILABILITY & …
www.cdsco.nic.inGUIDELINES FOR BIOAVAILABILITY & BIOEQUIVALENCE STUDIES Central Drugs Standard Control Organization, Directorate General of Health Services, Ministry of Health & Family Welfare,
STRUCTURE of periodic safety update report - …
www.dec.gov.uaSTRUCTURE of periodic safety update report Title page Executive Summary Contents of periodic safety update report I. Introduction II. Worldwide registration status
Module VII VII.B.5 Format and contents of the PSUR
www.jfda.joimportant safety findings from use of the combination therapy. If the product itself is a fixed combination product, this PSUR sub-section should …
DATA SHEET - Medsafe
www.medsafe.govt.nzVIREAD Data Sheet (14 July 2017) 2 of 46 illnesses or the need for treatment with other medicinal products concomitantly with VIREAD should be taken into consideration.
Public Assessment Report Decentralised Procedure …
www.mhra.gov.ukPublic Assessment Report Decentralised Procedure Sirdupla 25 microgram/125 microgram per metered dose pressurised inhalation, suspension Sirdupla 25 microgram/250 microgram per metered
Related search queries
PL 00010/0643, Clinical, Medicinal, Requirements for clinical documentation for, Clinical development of fixed, Clinical development of fixed combination medicinal, INVESTIGATION OF BIOAVAILABILITY AND, OF BIOAVAILABILITY AND BIOEQUIVALENCE, GUIDELINES FOR BIOAVAILABILITY, STRUCTURE of periodic safety update report, Of periodic safety update report, VII VII.B.5 Format and contents of, Combination, Fixed combination, Data Sheet, Public Assessment Report Decentralised Procedure